ABCDEFGHIJKLMNOPQRSTUVWXYZAA
1
I approveNameInstitution(s)DepartmentAddressemailORCIDPresent Address (if different from current)Conflict of interest disclosureFunding acknowledgements
2
XMatthew C. RobinsonPostEra Inc.Technology1 Broadway, 14th Floor, Cambridge, MA, 02142matthew.robinson@postera.ai
3
xNir LondonThe Weizmann Institute of ScienceChemical and Structural BiologyHertzl 234 st. Rehovot, Israel, 7610001nir.london@weizmann.ac.il0000-0003-2687-0699
N.L. currently serves on the scientific advisory board of Monte Rosa Therapeutics, Larkspur Biosciences and Tesseract Medicines
N.L. would like to acknowledge funding from the Israel Science Foundation (grant no. 3824/19), the Estate of Emile Mimran, Honey and Dr. Barry Sherman Lab, Dr. Barry Sherman Institute for Medicinal Chemistry and Nelson P. Sirotsky.
4
xEfrat ResnickThe Weizmann Institute of ScienceChemical and Structural BiologyHertzl 234 st. Rehovot, Israel, 7610001efrat.resnick@weizmann.ac.il0000-0001-9497-0216
5
xDaniel ZaidmannThe Weizmann Institute of ScienceChemical and Structural BiologyHertzl 234 st. Rehovot, Israel, 7610001daniel.zaidman@gmail.com
6
xPaul GehrtzThe Weizmann Institute of ScienceChemical and Structural BiologyHertzl 234 st. Rehovot, Israel, 7610001paul.gehrtz@merckgroup.com
Merck Healthcare KGaA, Frankfurter Str 250, 64293 Darmstadt, Germany
7
XRambabu N. ReddiThe Weizmann Institute of ScienceChemical and Structural BiologyHertzl 234 st. Rehovot, Israel, 7610001rambabu.reddi78@gmail.com
8
xRonen GabizonThe Weizmann Institute of ScienceChemical and Structural BiologyHertzl 234 st. Rehovot, Israel, 7610001ronen.gabizon@weizmann.ac.il
9
XHaim BarrThe Weizmann Institute of Science
Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine
Hertzl 234 st. Rehovot, Israel, 7610001haim.barr@weizmann.ac.il0000-0001-9192-3983
10
XShirly DubersteinThe Weizmann Institute of Science
Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine
Hertzl 234 st. Rehovot, Israel, 7610001shirly.valter@weizmann.ac.il
11
XHadeer ZidaneThe Weizmann Institute of Science
Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine
Hertzl 234 st. Rehovot, Israel, 7610001hadeer.zidane@weizmann.ac.il
12
XKhriesto ShurrushThe Weizmann Institute of Science
Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine
Hertzl 234 st. Rehovot, Israel, 7610001khriesto.shurrush@weizmann.ac.il
13
XGalit CohenThe Weizmann Institute of Science
Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine
Hertzl 234 st. Rehovot, Israel, 7610001galit.cohen@weizmann.ac.il
14
xLeonardo J. SolmeskyThe Weizmann Institute of Science
Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine
Hertzl 234 st. Rehovot, Israel, 7610001leonardo.solmesky@weizmann.ac.il
15
xAlpha LeePostEra Inc.; University of Cambridge1 Broadway, 14th Floor, Cambridge, MA, 02142alpha.lee@postera.ai
16
xAndrew JajackPostEra Inc.Technology1 Broadway, 14th Floor, Cambridge, MA, 02142ajajack@gmail.com
17
xMilan CvitkovicPostEra Inc.Technology1 Broadway, 14th Floor, Cambridge, MA, 02142mwcvitkovic@gmail.com0000-0003-4188-452X
18
xJin PanPostEra Inc.Technology1 Broadway, 14th Floor, Cambridge, MA, 02142jin@thepanda.family
19
xRuby PaiPostEra Inc.Technology1 Broadway, 14th Floor, Cambridge, MA, 02142rubyjpai@gmail.com
20
XEmily Grace RipkaPostEra Inc.Technology1 Broadway, 14th Floor, Cambridge, MA, 02142emily.ripka@postera.ai
21
xLuong NguyenPostEra Inc.Technology1 Broadway, 14th Floor, Cambridge, MA, 02142luong.nguyen@postera.ai
22
xMikhail ShafeevEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukrainem.shafeev@mail.enamine.net
23
xTatiana MatviiukEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukrainet.matviyuk@enamine.net
24
XOleg MichurinEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukraineo.michurin@enamine.net
25
xEugene ChernyshenkoEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukrainey.chernyshenko@enamine.net
26
XVitaliy A. BilenkoEnamine Ltd, Taras Shevchenko National University of KyivSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukrainev.bilenko@enamine.net
27
XSerhii O. KinakhEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukraines.kinakh@enamine.net
28
xIvan G. LogvinenkoEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukrainei.logvinenko@enamine.net
29
XKostiantyn P. MelnykovEnamine Ltd, Taras Shevchenko National University of KyivSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukraine, 60 Volodymyrska Street, Kyiv, Ukraine, 01033k.melnykov@enamine.net
30
xVictor D. HuliakEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukrainev.huliak@mail.enamine.net
31
xIgor S. TsurupaEnamine LtdSynthetic Chemistry78 Chervonotkatska Street, 02094 Kyiv, Ukraineigortsurupa@gmail.com
32
xMarian GorichkoTaras Shevchenko National University of KyivOrganic Chemistry60 Volodymyrska Street, Kyiv, Ukraine, 01033417lab@gmail.com0000-0002-5401-9597
33
Aarif ShaikhSai Life SciencesSynthetic Chemistry
Sai Life Sciences Limited, DS-7, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India, Phone No: +91 40 8418662201
aarif.s@sailife.com
34
xJakir PinjariSai Life SciencesSynthetic Chemistry
Sai Life Sciences Limited, DS-7, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India, Phone No: +91 40 8418662201
jakir.pinjari@sparcmail.com
Sun Pharma Advanced Research Company (SPARC), Baroda, India.
35
xVishwanath SwamySai Life SciencesSynthetic Chemistry
Sai Life Sciences Limited, DS-7, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India, Phone No: +91 40 8418662201
vishwanath.swamy@tcgls.com TCG Life Sciences, Pune, India.
36
XManeesh PingleSai Life SciencesSynthetic Chemistry
Sai Life Sciences Limited, DS-7, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India, Phone No: +91 40 8418662201
maneesh.p@sailife.com
37
XSarma BVNBSSai Life SciencesSynthetic Chemistry
Sai Life Sciences Limited, DS-7, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India, Phone No: +91 40 8418662201
sarma.b@sailife.com
38
XAnthony AimonDiamond Light Source Ltd; Research Complex at Harwell
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
anthony.aimon@gmail.com0000-0002-9135-129X
39
XFrank von DelftDiamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Centre for Medicine Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom;Department of Biochemistry, University of Johannesburg, Auckland Park, 2006, South Africa
frank.von-delft@diamond.ac.uk0000-0003-0378-0017
F.v.D. acknowledges funding from the Wellcome Trust (grant no. 106169/ZZ14/Z) and BBSRC (grant no. BB/T003677/1)
40
XDaren FearonDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
daren.fearon@diamond.ac.uk0000-0003-3529-7863
41
XCharles W.E. TomlinsonDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
charlie.tomlinson@diamond.ac.uk0000-0002-1845-6028
42
xBlake H. BalcombDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
blake.h.balcomb@diamond.ac.uk0000-0001-7599-8467
43
xRyan M. LithgoDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
ryan.lithgo@diamond.ac.uk0000-0002-4706-9916
44
xJasmin C. Aschenbrenner Diamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
jasmin.aschenbrenner@diamond.ac.uk0000-0002-4318-0481
45
xLouise E. DunnettDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
louise.dunnett@diamond.ac.uk0000-0001-6710-6959
46
Alice DouangamathDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
alice.douangamath@gmx.de0000-0002-9196-8644
47
xAlex DiasDiamond Light Source Ltd; Research Complex at HarwellCEO
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
alexandre.dias@diamond.ac.uk0000-0003-3609-7003
48
xAilsa PowellDiamond Light Source Ltd; Research Complex at HarwellCEO
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
ailsa.powell@diamond.ac.uk0000-0002-0462-2240
49
xJose Brandao NetoDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
jose.brandao-neto@diamond.ac.uk0000-0001-6015-320X
50
xRachael SkynerDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
Rachael.Skyner@omass.com0000-0003-3614-6661
51
XWarren ThompsonDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
warren.thompson@diamond.ac.uk0000-0003-1474-7810
52
XTyler Gorrie-StoneDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
tyler.gorrie-stone@genomicsplc.com0000-0002-1817-1495
53
XMartin A. WalshDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
martin.walsh@diamond.ac.uk0000-0001-5683-1151
54
XC. David OwenDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
david.owen@diamond.ac.uk0000-0001-5774-8202
55
XPetra LukacikDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
petra.lukacik@diamond.ac.uk0000-0002-3179-7273
56
XClaire Strain-DamerellDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
claire.strain-damerell@diamond.ac.uk0000-0003-4964-2090
57
xHalina MikolajekDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
halina.mikolajek@diamond.ac.uk0000-0003-0776-9974
58
XSam HorrellDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
sam.horrell@diamond.ac.uk0000-0001-6355-8640
59
XPeter G. MarplesDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
peter.marples@diamond.ac.uk0000-0002-8787-7969
60
xLizbé KoekemoerUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKlizbe.koekemoer@cmd.ox.ac.uk0000-0001-9226-9127
L.K. acknowledges funding from the Wellcome Trust (grant no. 106169/ZZ14/Z)
61
xTobias KrojerUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKtobias.krojer@maxiv.lu.se0000-0003-0661-0814
MAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden
T.K. acknowledges funding from the Wellcome Trust (grant no. 106169/ZZ14/Z)
62
xMichael FairheadUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKmichael.fairhead@cmd.ox.ac.uk0000-0001-5361-3933
M.F. acknowledges funding from the BBSRC (grant no. BB/T003677/1)
63
XElizabeth M. MacLeanUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKbeth.maclean@cmd.ox.ac.uk0000-0003-1680-4292
E.M. acknowledges funding from the Wellcome Trust (grant no. 106169/ZZ14/Z)
64
XAndrew ThompsonUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKthompson.a@wehi.edu.au0000-0002-3910-2317
Walter and Eliza Hall Institute. 1G Royal Parade, Parkville 3052, Victoria, Australia
65
XConor Francis WildDiamond Light Source Ltd; Research Complex at HarwellLife Sciences
Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom
c.wild@diamond.ac.uk0000-0003-0654-8141
66
XMihaela D. SmilovaUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKmihaela.smilova@gmail.com0000-0001-6255-7312
67
XNathan WrightUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKnathan.wright@cmd.ox.ac.uk0000-0001-5035-8180
N.W. acknowledges funding from the Wellcome Trust (grant no. 106169/ZZ14/Z)
68
XAnnette von DelftUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKannette.vondelft@cmd.ox.ac.uk0000-0002-7699-8140
A.v.D acknowledges funding from the Wellcome Trust (grant no. 106169/ZZ14/Z), and the Oxford Biomedical Research Centre, BRC, NIHR
69
xCarina GileadiUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKcarinagileadi@hotmail.com
Salary support received from the John Fell Fund Oxford
70
xVictor L. RangelSchool of Pharmaceutical Sciences of Ribeirao PretoPharmaceutical SciencesAvenida do Café, s/nºRibeirão Preto - SP/CEP 14040-903victorlopesrangel92@gmail.com0000-0002-7580-3452
Evotec (UK) Ltd. 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, United Kingdom
Financed by National Council for Scientific and Technological Development
(CNPq, grant number 141945/2018-4) and financed in part by the Coordenação de Aperfeiçoamento
de Pessoal de Nível Superior - Brasil (CAPES) – Finance Code 001
71
XChristopher J. SchofieldUniversity of OxfordDepartment of ChemistryChemistry Research Laboratory, 12 Mansfield Rd, Oxford OX1 3TA, United Kingdomchristopher.schofield@chem.ox.ac.uk0000-0002-0290-6565
Supported by the Univeristy of Oxford COVID-19 Research Resposne Fund, the Wellcome Trust, CRUK and The BBSRC
72
xEidarus SalahUniversity of OxfordDepartment of ChemistryChemistry Research Laboratory, 12 Mansfield Rd, Oxford OX1 3TA, United Kingdomeidarus.salah@chem.ox.ac.uk0000-0001-7552-4966
Supported by the Univeristy of Oxford COVID-19 Research Resposne Fund, the Wellcome Trust, CRUK and The BBSRC
73
XTika R. MallaUniversity of OxfordNuffield Department of MedicineCentre for Medicines Discovery, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKtika.malla@cmd.ox.ac.uk0000-0003-4989-6410
Supported by the Univeristy of Oxford COVID-19 Research Resposne Fund, the Wellcome Trust, CRUK and The BBSRC
74
XAnthony TumberUniversity of OxfordDepartment of ChemistryChemistry Research Laboratory, 12 Mansfield Rd, Oxford OX1 3TA, United Kingdomanthony.tumber@chem.ox.ac.uk
Supported by the Univeristy of Oxford COVID-19 Research Resposne Fund, the Wellcome Trust, CRUK and The BBSRC
75
XTobias JohnUniversity of OxfordDepartment of ChemistryChemistry Research Laboratory, 12 Mansfield Rd, Oxford OX1 3TA, United Kingdomtobias.john1@gmx.de0000-0002-6123-595XAMSilk, Anna-Sigmund-Str. 1-3, 82061 Neuried
T.J. was supported by the Oxford-GSK-Crick Doctoral Programme in Chemical Biology, EPSRC (EP/R512060/1) and GlaxoSmithKline
76
XIoannis VakonakisUniversity of OxfordDepartment of BiochemistrySouth Parks Road, Oxford OX1 3QUjvakon@gmail.com0000-0002-4726-0446
Lonza Biologics, Lonza Ltd, Lonzastrasse, CH-3930 Visp, Switzerland.
Supported by the University of Oxford COVID-19 Research Response Fund
77
XAnastassia L. KantsadiUniversity of OxfordDepartment of BiochemistrySouth Parks Road, Oxford OX1 3QUAkantsadi@uth.gr
Department of Biochemistry and Biotechnology, University of Thessaly, Greece
Supported by the Oxford Glycobiology Institute Endowment
78
XNicole ZitzmannUniversity of OxfordDepartment of Biochemistry
Oxford Glycobiology Institute and Kavli Institute of Nanoscience Discovery; South Parks Road, Oxford OX1 3QU
nicole.zitzmann@bioch.ox.ac.uk0000-0003-1969-4949
Supported by the University of Oxford COVID-19 internal funds, the Oxford Glycobiology Institute Endowment, and grants to Biochemistry Department Oxford, the Dunn School of Pathology.
79
XJuliane BrunUniversity of OxfordDepartment of Biochemistry
Oxford Glycobiology Institute and Kavli Institute of Nanoscience Discovery; South Parks Road, Oxford OX1 3QU
juliane.brun@bioch.ox.ac.uk0000-0002-0964-3681
Supported by the University of Oxford COVID-19 internal funds, the Oxford Glycobiology Institute Endowment, and grants to Biochemistry Department Oxford, the Dunn School of Pathology.
80
xJ. L. KiappesUniversity of OxfordDepartment of BiochemistryOxford Glycobiology Institute; South Parks Road, Oxford OX1 3QUj.l.kiappes@ucl.ac.uk0000-0001-6697-6776
Department of Chemistry, 20 Gordon Street, London WC1H 0AJ
Supported by the University of Oxford COVID-19 internal funds, the Oxford Glycobiology Institute Endowment, and grants to Biochemistry Department Oxford, the Dunn School of Pathology.
81
xMichelle HillUniversity of OxfordDepartment of BiochemistryOxford Glycobiology Institute; South Parks Road, Oxford OX1 3QUmichelle.hill@path.ox.ac.uk0000-0002-9289-5811
Sir William Dunn School of Pathology, South Parks Road, Oxford. OX1 3RE
Supported by the University of Oxford COVID-19 internal funds, the Oxford Glycobiology Institute Endowment, and grants to Biochemistry Department Oxford, the Dunn School of Pathology.
82
xKarolina D WittUniversity of OxfordNuffield Department of MedicinePandemic Sciences Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford, Oxon, OX3 7DQ, UKkarolina.witt@ndm.ox.ac.uk0000-0001-6230-2133
83
xDominic S AlonziUniversity of OxfordDepartment of BiochemistryOxford Glycobiology Institute; South Parks Road, Oxford OX1 3QUdominic.alonzi@bioch.ox.ac.uk0000-0002-1330-9109
84
XLaetitia L MakowerUniversity of OxfordDepartment of BiochemistryOxford Glycobiology Institute; South Parks Road, Oxford OX1 3QUlettymakower@gmail.com0000-0003-2385-3973
85
XFinny S. VargheseRadboud University Medical CenterDepartment of Medical Microbiology
Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands
F.Varghese@uniqure.com0000-0002-7900-5482
uniQure Biopharma, Amsterdam, the Netherlands
none
86
XGijs J. OverheulRadboud University Medical CenterDepartment of Medical Microbiology
Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands
Gijs.Overheul@radboudumc.nl0000-0002-8356-8165none
87
XPascal MiesenRadboud University Medical CenterDepartment of Medical Microbiology
Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands
pascal.miesen@radboudumc.nl0000-0002-6378-0871none
PM acknowledges support from the Dutch Research Council (grant no. VI.Veni.202.035)
88
XRonald P. van RijRadboud University Medical CenterDepartment of Medical Microbiology
Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands
ronald.vanrij@radboudumc.nl0000-0003-0221-4689none
RPvR acknowledges funding from the Dutch Research Council (grant no. 016.VICI.170.090)
89
XJitske JansenRWTH Aachen UniversityInstitute of Experimental Medicine and Systems Biology
Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Pauwelsstrasse 30 52074 Aachen, Germany.
Jijansen@radboudumc.nl0000-0003-0513-6102none
JJ acknowledges funding from the Dutch Research Council (grant no. Veni 091.501.6181.01.36)
90
XBart SmeetsRadboud University Medical CenterDepartment of Pathology
Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 28, 6525 GA Nijmegen, The Netherlands
Bart.Smeets@radboudumc.nl0000-0002-8466-3367
BS acknowledges funding from the Dutch Research Council (grant no. VIDI 016.156.363)
91
xSusana TomásioCollaborative Drug DiscoveryNine Hills Rd, Cambridge, CB2 1GE, UKStomasio@collaborativedrug.com
92
xCharlie WeatherallCollaborative Drug Discovery1633 Bayshore Hwy, Burlingame, CA 94010, USAcweatherall@collaborativedrug.com
93
xMariana VaschettoCollaborative Drug DiscoveryNine Hills Rd, Cambridge, CB2 1GE, UKmariana@collaborativedrug.com
94
XHannah Bruce MacdonaldSloan Kettering Institute, Memorial Sloan Kettering Cancer CenterComputational and Systems Biology Program1275 York Ave, New York, NY 10065hannah.brucemacdonald@choderalab.org0000-0002-5562-6866
Charm Therapeutics, 7 Pancras Sq, London, N1C 4AG, UK
95
XJohn D. ChoderaSloan Kettering Institute, Memorial Sloan Kettering Cancer CenterComputational and Systems Biology Program1275 York Ave ZRC 6-South, New York, NY 10065john.chodera@choderalab.org0000-0003-0542-119X
JDC is a current member of the Scientific Advisory Board of OpenEye Scientific Software, Redesign Science, Ventus Therapeutics, and Interline Therapeutics, and has equity interests in Rede and Interline Therapeutics.
The Chodera laboratory receives or has received funding from multiple sources, including the National Institutes of Health, the National Science Foundation, the Parker Institute for Cancer Immunotherapy, Relay Therapeutics, Entasis Therapeutics, Silicon Therapeutics, EMD Serono (Merck KGaA), AstraZeneca, Vir Biotechnology, Bayer, XtalPi, Interline Therapeutics, the Molecular Sciences Software Institute, the Starr Cancer Consortium, the Open Force Field Consortium, Cycle for Survival, a Louis V.\ Gerstner Young Investigator Award, and the Sloan Kettering Institute.
A complete funding history for the Chodera lab can be found at http://choderalab.org/funding.The Chodera laboratory receives or has received funding from multiple sources, including the National Institutes of Health, the National Science Foundation, the Parker Institute for Cancer Immunotherapy, Relay Therapeutics, Entasis Therapeutics, Silicon Therapeutics, EMD Serono (Merck KGaA), AstraZeneca, Vir Biotechnology, Bayer, XtalPi, Foresite Laboratories, the Molecular Sciences Software Institute, the Starr Cancer Consortium, the Open Force Field Consortium, Cycle for Survival, a Louis V. Gerstner Young Investigator Award, and the Sloan Kettering Institute.
A complete funding history for the Chodera lab can be found at http://choderalab.org/funding
JDC acknowledges support from NSF RAPID 2033426, NIH grant P30 CA008748, NIH grant R01 GM121505, NIH grant R01 GM132386, NSF CHE-1904822, and the Sloan Kettering Institute.
96
xDominic A. RufaSloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Computational and Systems Biology Program ; Tri-Institutional Program in Chemical Biology
1275 York Ave ZRC 6-South, New York, NY 10065dominic.rufa@choderalab.org0000-0003-0930-9445
DAR acknowledges support from the Tri-Institutional Program in Chemical Biology
97
XMatthew WittmannSloan Kettering Institute, Memorial Sloan Kettering Cancer CenterComputational and Systems Biology Program1275 York Ave ZRC 6-South, New York, NY 10065mcwitt@gmail.com0000-0003-0948-40830000-0003-0948-4083
MW acknowledges support from NSF RAPID 2033426 and the Sloan Kettering Institute
98
XMelissa L. BobySloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Computational and Systems Biology Program ; Pharmacology Graduate Program
1275 York Ave ZRC 6-South, New York, NY 10065melissa.boby@choderalab.org0000-0003-1920-206X
MB acknowledges support from the Sloan Kettering Institute
99
XMichael HenrySloan Kettering Institute, Memorial Sloan Kettering Cancer CenterComputational and Systems Biology Program1275 York Ave ZRC 6-South, New York, NY 10065mike.henry@choderalab.org0000-0002-3870-9993
MB acknowledges support from the Sloan Kettering Institute
100
XWilliam G. GlassSloan Kettering Institute, Memorial Sloan Kettering Cancer CenterComputational and Systems Biology Program1275 York Ave ZRC 6-South, New York, NY 10065william.glass@choderalab.org0000-0002-4099-9280
Exscientia, The Schrödinger Building, Oxford Science Park, Oxford, OX4 4GE, UK